Aziyo Biologics, Inc. Class A ( (ELUT) ) has released its Q4 earnings. Here is a breakdown of the information Aziyo Biologics, Inc. Class A presented to its investors.
Elutia Inc., a leader in drug-eluting biomatrix technologies, focuses on enhancing the compatibility between medical devices and patients, particularly in the cardiac and neurostimulator sectors.
In its latest earnings report, Elutia announced a successful pilot launch of EluPro™, an FDA-cleared antibiotic-eluting biomatrix, which has seen strong demand and is poised for a full commercial rollout. The company reported a significant increase in BioEnvelope sales, driven by EluPro’s market entry.
Key financial highlights include an 18% rise in BioEnvelope sales during the fourth quarter, with EluPro accounting for a substantial portion of these sales. Despite a 1.5% overall decrease in net sales for the year, driven by a shift in cardiovascular product strategies, Elutia achieved a strong adjusted gross margin of 57.9%. The company also bolstered its financial position with a $15 million capital raise.
Looking ahead, Elutia’s management remains optimistic about the continued adoption of EluPro and its potential to capture a significant share of the $600 million market for cardiac and neurostimulator device protection.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com